Found: 616
Select item for more details and to access through your institution.
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri<sup>®</sup>) Dosing: NOVA Phase IIIb Extension Study (Part 2).
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 5, p. 1385, doi. 10.1007/s40120-024-00647-0
- By:
- Publication type:
- Article
Characterizing interstitial lung disease in patients with psoriasis: a cross-sectional analysis in the National Institutes of Health's All of Us Research Program.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 9, p. 1083, doi. 10.1093/ced/llae132
- By:
- Publication type:
- Article
Association of lichen planus with asthma and allergic rhinitis in the All of Us Research Program: a cross-sectional study.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 9, p. 1067, doi. 10.1093/ced/llae101
- By:
- Publication type:
- Article
A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion.
- Published in:
- PLoS Pathogens, 2024, v. 20, n. 9, p. 1, doi. 10.1371/journal.ppat.1012477
- By:
- Publication type:
- Article
Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control study.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Postcolonial Approaches to the European Middle Ages: Translating Cultures.
- Published in:
- 2006
- By:
- Publication type:
- Book Review
Dermatologist and pharmacist perspectives of a collaborative co-management program.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Association between psoriasis and obsessive-compulsive disorder: a case-control study in the All of Us research program.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Barriers to care and health-related quality of life among US adults with several common chronic inflammatory skin diseases: a cross-sectional analysis of the NIH All of Us Research Program.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Comorbid psychiatric disease significantly mediates increased rates of alcohol use disorder among patients with inflammatory and pigmentary skin disorders: a case–control study in the All of Us Research Program.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 2, p. 1, doi. 10.1007/s00403-023-02803-2
- By:
- Publication type:
- Article
Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research program.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Association between uveitis and Lichen planus in the all of us research program.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 9, p. 2729, doi. 10.1007/s00403-023-02675-6
- By:
- Publication type:
- Article
Association of atopic dermatitis with schizophrenia and schizoaffective disorder.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 9, p. 2731, doi. 10.1007/s00403-023-02674-7
- By:
- Publication type:
- Article
Psoriasis associated with asthma and allergic rhinitis: a US-based cross-sectional study using the All of US Research Program.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 6, p. 1823, doi. 10.1007/s00403-023-02539-z
- By:
- Publication type:
- Article
Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 5, p. 1439, doi. 10.1007/s00403-022-02488-z
- By:
- Publication type:
- Article
Lichen planus is associated with depression and anxiety: a cross-sectional study in the All of Us research program.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 5, p. 1417, doi. 10.1007/s00403-022-02459-4
- By:
- Publication type:
- Article
Prevalence of eczema among adults in the United States: a cross-sectional study in the All of Us research program.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 4, p. 999, doi. 10.1007/s00403-022-02328-0
- By:
- Publication type:
- Article
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 3, p. 429, doi. 10.1007/s00403-022-02369-5
- By:
- Publication type:
- Article
Autoimmune comorbidities associated with sarcoidosis: a case-control study in the All of Us research program.
- Published in:
- Rheumatology Advances in Practice, 2023, v. 7, n. 2, p. 1, doi. 10.1093/rap/rkad030
- By:
- Publication type:
- Article
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine.
- Published in:
- NPJ Vaccines, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41541-022-00535-4
- By:
- Publication type:
- Article
Babyboomers, Inc.
- Published in:
- Issues in Accounting Education, 1997, v. 12, n. 2, p. 413
- By:
- Publication type:
- Article
An Analysis of Underlying Constructs Affecting the Choice of Accounting as a Major.
- Published in:
- Issues in Accounting Education, 1993, v. 8, n. 2, p. 219
- By:
- Publication type:
- Article
Cases in Ethics and Professionalism.
- Published in:
- 1990
- By:
- Publication type:
- Book Review
Accounting Educators' Perceptions of Ethics in the Curriculum.
- Published in:
- Issues in Accounting Education, 1989, v. 4, n. 1, p. 70
- By:
- Publication type:
- Article
The Historical Memory of American Presidents in the Mass Public.
- Published in:
- Social Sciences (2076-0760), 2018, v. 7, n. 3, p. 36, doi. 10.3390/socsci7030036
- By:
- Publication type:
- Article
Multiple sclerosis can be diagnosed solely with dissemination in space: Commentary.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 6, p. 641, doi. 10.1177/13524585241245319
- By:
- Publication type:
- Article
Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 3, p. 369, doi. 10.1177/13524585231224702
- By:
- Publication type:
- Article
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 2, p. 177, doi. 10.1177/13524585231216854
- By:
- Publication type:
- Article
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 11/12, p. 1452, doi. 10.1177/13524585231195346
- By:
- Publication type:
- Article
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 10, p. 1257, doi. 10.1177/13524585231187289
- By:
- Publication type:
- Article
Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol 2023; 22(8): 750–768.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 9, p. 1047, doi. 10.1177/13524585231188097
- By:
- Publication type:
- Article
The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 7, p. 846, doi. 10.1177/13524585231172490
- By:
- Publication type:
- Article
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 1, p. 92, doi. 10.1177/13524585221122156
- By:
- Publication type:
- Article
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 14, p. 2177, doi. 10.1177/13524585221116269
- By:
- Publication type:
- Article
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
- By:
- Publication type:
- Article
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 11, p. 1729, doi. 10.1177/13524585221094239
- By:
- Publication type:
- Article
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1562, doi. 10.1177/13524585221078825
- By:
- Publication type:
- Article
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 7, p. 1131, doi. 10.1177/13524585211061343
- By:
- Publication type:
- Article
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 817, doi. 10.1177/13524585211035333
- By:
- Publication type:
- Article
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 14, p. 2219, doi. 10.1177/13524585211000280
- By:
- Publication type:
- Article
Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 11, p. 1749, doi. 10.1177/1352458520981736
- By:
- Publication type:
- Article
MRI findings in blinded trials should be available to treating physicians – No.
- Published in:
- Multiple Sclerosis Journal, 2021, v. 27, n. 6, p. 814, doi. 10.1177/1352458520986959
- By:
- Publication type:
- Article
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 12, p. 1581, doi. 10.1177/1352458519867314
- By:
- Publication type:
- Article
Response of the multiple sclerosis community to COVID-19.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
MSJ 2020 – Editorial comment.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 1, p. 23, doi. 10.1177/1352458519892555
- By:
- Publication type:
- Article
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 13, p. 1781, doi. 10.1177/1352458518808204
- By:
- Publication type:
- Article
The emergence of follow-on disease-modifying therapies for multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1560, doi. 10.1177/1352458519845106
- By:
- Publication type:
- Article
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 12, p. 1605, doi. 10.1177/1352458518796675
- By:
- Publication type:
- Article
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1255, doi. 10.1177/1352458518789884
- By:
- Publication type:
- Article